Legal & General Group’s Beam Therapeutics BEAM Stock Holding History
Bought
Maintained
Sold
Other funds holding BEAM
FCM
AIM
AVM
NAMA
Legal & General Group's BEAM Position: Q2 2026 in Review
Legal & General Group reduced its Beam Therapeutics (BEAM) stake by 3.3% in Q2 2026, selling an estimated $82.5K and leaving 79,179 shares worth $2.72M. The position accounts for ﹤0.01% of the portfolio, ranked #1843.
Legal & General Group first reported a position in BEAM in Q1 2020 and has held it in 26 quarters since. The position peaked at $3.77M in Q2 2021. 277 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.
- Legal & General Group held 79,179 shares of Beam Therapeutics worth $2.72M as of Q2 2026.
- Legal & General Group sold 2,733 Beam Therapeutics shares in Q2 2026, an estimated $82.5K.
- Beam Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #1843 holding.
- Legal & General Group first reported a position in Beam Therapeutics in Q1 2020 and has held it in 26 quarters since.
- Legal & General Group's Beam Therapeutics position peaked at $3.77M in Q2 2021.
- 277 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.
Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.